Jay Edelberg
Director/Board Member at Prolaio, Inc.
Profile
Presently, Jay Edelberg holds the position of Senior Vice President-Clinical Development at MyoKardia, Inc. In his past career he occupied the position of Head-Development & Launch Unit at Sanofi. Dr. Edelberg received a doctorate from Duke University.
Jay Edelberg active positions
| Companies | Position | Start |
|---|---|---|
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Director/Board Member | - |
Former positions of Jay Edelberg
| Companies | Position | End |
|---|---|---|
| MYOKARDIA, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
| SANOFI | Corporate Officer/Principal | - |
Training of Jay Edelberg
| Duke University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SANOFI | Health Technology |
| Private companies | 2 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
- Stock Market
- Insiders
- Jay Edelberg
